VipBlogSpots

The non-invasive cancer diagnostics market is projected to grow at an annualized rate of ~20%, till

Roots Analysis has done a detailed study on Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exos...
Roots Analysis has done a detailed study on Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. To order this 350+ page report, which features 150+ figures and 200+ tables, please visit this link Key Market Insights For more information, please visit https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html                                                                                                                 Table of Contents 1.1.              Scope of the Report 1.2.              Research Methodology 1.3.              Chapter Outlines 3.1.              Chapter Overview 3.2.              Cancer Statistics and Burden of the Disease 3.3.              Importance of Early Cancer Detection 3.4.              Cancer Screening and Diagnosis 3.5.              Conventional Invasive Cancer Diagnostic Tests 3.5.1.           Biopsy 3.5.1.1.
       Fine Needle Aspiration Biopsy 3.5.1.2.        Core Needle Biopsy 3.5.1.3.
       Vacuum-Assisted Biopsy 3.5.1.4.        Image-Guided Biopsy Press Release: Variation 2 (Format 3) 3.5.1.5.
       Sentinel Node Biopsy 3.5.1.6.        Surgical Biopsy 3.5.1.7.
       Endoscopic Biopsy 3.5.1.8.        Bone Marrow Biopsy 3.5.2.           Endoscopy 3.6.              Need for Non-Invasive Approaches 3.7.              Liquid Biopsy: Diagnosing Circulating Biomarkers 3.7.1.           Circulating Tumor Cells 3.7.2.           Circulating Tumor DNA 3.7.3.           Exosomes             3.8.              Costs and Benefits Associated with Liquid Biopsy and Non-Invasive Tests 3.9.              Emerging Trends in Intellectual Property Related to Non-Invasive Cancer Diagnostics 3.10.            Challenges Associated with Non-Invasive Cancer Diagnostics 3.11.            Future Perspectives 4.1.              Chapter Overview 4.2.              Diagnostic Imaging 4.2.1.           Magnetic Resonance Imaging (MRI) 4.2.2.           Mammography 4.2.3.           Bone Scan 4.2.4.           Computerized Tomography (CT) Scan 4.2.5.           Integrated Positron Emission Tomography (PET)-CT Scan 4.2.6.           Ultrasound 4.2.7.           X-ray Radiography (Barium Enema) 4.3.              Screening Assays 4.3.1.           Circulating Tumor Marker Test 4.3.2.           Digital Rectal Exam (DRE) 4.3.3.           Fecal Occult Blood Test (FOBT) 4.3.4.           Multigated Acquisition (MUGA) Scan 4.3.5.           Papanicolaou Test and Human Papilloma Virus Test 4.4.              Advanced Non-Invasive Approaches 4.4.1.           Cytogenetic / Gene Expression Studies 4.4.2.           Molecular Signature-based Non-Invasive Methods 4.4.3.           Saliva-based Oral Cancer Diagnostics 4.4.4.           Vital Staining 4.4.5.           Optical Biopsy 4.4.6.           Other Diagnostic Techniques 5.1.              Chapter Overview 5.2.              Liquid Biopsy Products: List of Developers 5.2.1.           Analysis by Year of Establishment 5.2.2.           Analysis by Company Size and Geographical Location 5.2.3.           Leading Players 5.2.4.           Analysis by Geography 5.3.              Liquid Biopsy Products: List of Available / Under Development Products 5.3.1.           Analysis by Status of Development 5.3.2.           Analysis by Type of Product 5.3.3.           Analysis by Application Area Press Release: Variation 2 (Format 3) 5.3.4.           Analysis by Target Cancer Indication 5.3.5.           Analysis by Type of Tumor Marker 5.3.6.           Analysis by End User 5.3.7.           Analysis by Turnaround Time 5.4.              Liquid Biopsy Products: List of Other Products, Kits and Consumables 5.5.              Liquid Biopsy Products: List of Contract Service Providers 6.1.              Chapter Overview 6.2.              Amoy Diagnostics 6.2.1.           Company Overview 6.2.2.           Financial Information 6.2.3.           Liquid Biopsy Product Portfolio 6.2.4.           Recent Developments and Future Outlook 6.3.              DiaCarta 6.3.1.           Company Overview 6.3.2.           Liquid Biopsy Product Portfolio 6.3.3.           Recent Developments and Future Outlook 6.4.              HaploX 6.4.1.           Company Overview 6.4.2.           Liquid Biopsy Product Portfolio 6.4.3.           Recent Developments and Future Outlook 6.5.              NeoGenomics 6.5.1.           Company Overview 6.5.2.           Financial Information 6.5.3.           Liquid Biopsy Product Portfolio 6.5.4.           Recent Developments and Future Outlook 6.6.              QIAGEN 6.6.1.           Company Overview 6.6.2.           Financial Information 6.6.3.           Liquid Biopsy Product Portfolio 6.6.4.           Recent Developments and Future Outlook 6.7.              Swift Biosciences 6.7.1.           Company Overview 6.7.2.           Liquid Biopsy Product Portfolio 6.7.3.           Recent Developments and Future Outlook 6.8.              Sysmex Inostics 6.8.1.           Company Overview 6.8.2.           Liquid Biopsy Product Portfolio 6.8.3.           Recent Developments and Future Outlook 6.9.              Thermo Fisher Scientific 6.9.1.           Company Overview 6.9.2.           Financial Information 6.9.3.           Liquid Biopsy Product Portfolio 6.9.4.           Recent Developments and Future Outlook 7.1.              Chapter Overview Press Release: Variation 2 (Format 3) 7.2.              Partnership Models 7.3.              List of Partnerships and Collaborations 7.3.1.           Analysis by Year of Partnership 7.3.2.           Analysis by Type of Partnership 7.3.3.           Analysis by Type of Tumor Marker 7.3.4.           Analysis by Target Cancer Indication 7.3.5.           Analysis by Type of Partner 7.3.6.           Most Active Players: Analysis by Number of Partnerships 7.3.7.           Regional Analysis 7.3.7.1.
       Intercontinental and Intracontinental Agreements 8.1.              Chapter Overview 8.2.              Types of Funding 8.3.              List of Funding and Investment Instances 8.3.1.           Analysis by Number of Funding Instances 8.3.2.           Analysis by Amount Invested 8.3.3.           Analysis by Type of Funding 8.3.4.           Analysis by Target Cancer Indication 8.3.5.           Analysis by Type of Tumor Marker 8.3.6.           Most Active Players: Analysis by Amount Invested 8.3.7.           Most Active Investors: Analysis by Number of Funding Instances 8.3.8.           Regional Analysis by Amount Invested 8.4.              Concluding Remarks 9.1.              Chapter Overview 9.2.              Top Pharmaceutical Companies 9.2.1.           Analysis by Status of Development 9.2.2.           Analysis by Type of Tumor Marker 9.2.3.           Analysis by Application Area 9.2.4.           Analysis by Target Cancer Indication 10.1.            Chapter Overview 10.2.            Scope and Methodology 10.3.            Scoring Criteria and Key Assumptions 10.4.            Potential Strategic Acquisition Targets in North America 10.5.            Potential Strategic Acquisition Targets in Europe 10.6.            Potential Strategic Acquisition Targets in Asia-Pacific / Rest of the World 10.7.            Concluding Remarks 11.1.            Chapter Overview 11.2.            Non-Blood-based Biomarker Detection Tests 11.3.            FOBT and Fecal Immunochemical Tests (FIT) 11.4.            Pigmented Lesion Assays 11.5.            Stool DNA (sDNA)-based Tests 11.6.            Volatile Organic Compound (VOC) Detection Tests 11.7.            Other Non-Invasive Cancer Diagnostics: Market Landscape 12.1.            Chapter Overview 12.2.            Key Assumptions and Forecast Methodology Press Release: Variation 2 (Format 3) 12.3.            Global Non-Invasive Cancer Diagnostics Market, 2019-2030 12.3.1.        Global Liquid Biopsy Market, 2019-2030 12.3.1.1.      Global Liquid Biopsy Market: Distribution by Application Area, 2019-2030 12.3.1.1.1.   Global Liquid Biopsy Market for Early Diagnosis, 2019-2030 12.3.1.1.2.
  Global Liquid Biopsy Market for Patient Monitoring, 2019-2030 12.3.1.1.3.   Global Liquid Biopsy Market for Recurrence Monitoring, 2019-2030 12.3.1.2.      Global Liquid Biopsy Market: Distribution by Target Cancer Indication, 2019-2030 12.3.1.2.1.
  Global Liquid Biopsy Market for Breast Cancer, 2019-2030 12.3.1.2.2.   Global Liquid Biopsy Market for Lung Cancer, 2019-2030 12.3.1.2.3.
  Global Liquid Biopsy Market for Colorectal Cancer, 2019-2030 12.3.1.2.4.   Global Liquid Biopsy Market for Prostate Cancer, 2019-2030 12.3.1.2.5.
  Global Liquid Biopsy Market for Bladder Cancer, 2019-2030 12.3.1.2.6.   Global Liquid Biopsy Market for Melanoma, 2019-2030 12.3.1.2.7.
  Global Liquid Biopsy Market for Gastric Cancer, 2019-2030 12.3.1.2.8.   Global Liquid Biopsy Market for Pancreatic Cancer, 2019-2030 12.3.1.2.9.
  Global Liquid Biopsy Market for Ovarian Cancer, 2019-2030           12.3.1.3.      Global Liquid Biopsy Market: Distribution by Type of Tumor Marker, 2019-2030 12.3.1.3.1.   Global Liquid Biopsy Market for ctDNA, 2019-2030 12.3.1.3.2.
  Global Liquid Biopsy Market for cfDNA, 2019-2030 12.3.1.3.3.   Global Liquid Biopsy Market for CTCs, 2019-2030 12.3.1.3.4.
  Global Liquid Biopsy Market for Exosomes, 2019-2030 12.3.1.3.5.   Global Liquid Biopsy Market for Other Tumor Markers, 2019-2030 12.3.1.4.      Global Liquid Biopsy Market: Distribution by Type of Analyte, 2019-2030 12.3.1.4.1.
  Global Liquid Biopsy Market for Blood, 2019-2030 12.3.1.4.2.   Global Liquid Biopsy Market for Other Body Fluids, 2019-2030 (USD Billion) 12.3.1.5.      Global Liquid Biopsy Market: Distribution by End User, 2019-2030 12.3.1.5.1.
  Global Liquid Biopsy Market for Hospitals, 2019-2030 12.3.1.5.2.   Global Liquid Biopsy Market for Research Institutes, 2019-2030 12.3.1.5.3.
  Global Liquid Biopsy Market for Other End Users, 2019-2030 12.3.1.6.      Global Liquid Biopsy Market: Distribution by Geography, 2019-2030 12.3.1.6.1.   Liquid Biopsy Market in the US, 2019-2030 12.3.1.6.2.
  Liquid Biopsy Market in the UK, 2019-2030 12.3.1.6.3.   Liquid Biopsy Market in Germany, 2019-2030 12.3.1.6.4.
  Liquid Biopsy Market in France, 2019-2030 12.3.1.6.5.   Liquid Biopsy Market in Italy, 2019-2030 12.3.1.6.6.
  Liquid Biopsy Market in Spain, 2019-2030 12.3.1.6.7. Liquid Biopsy Market in Japan, 2019-2030 12.3.1.6.8.   Liquid Biopsy Market in China, 2019-2030 12.3.1.6.9.
  Liquid Biopsy Market in India, 2019-2030 12.3.1.6.10. Liquid Biopsy Market in Australia, 2019-2030 12.3.2.        Other Non-Invasive Cancer Diagnostics Market Forecast, 2019-2030 13.1.            Chapter Overview 13.2.            Company Specifics of Respondents 13.3.            Designation of Respondents 13.4.            Type of Product Portfolio 13.5.            Types of Products / Services Offered 13.6.            Application Area Press Release: Variation 2 (Format 3) 13.7.            Status of Development of the Products 13.8.            Likely Market Size 14.1.            Timely Disease Detection and Subsequent Monitoring are Critical Elements of Patient Care           in the Field of Oncology 14.2.            Introduction of Sophisticated Molecular Diagnostics has Facilitated Better Cancer        Management 14.3.            Liquid Biopsy has Emerged as a Reliable Alternative to the Invasive Methods of Diagnosis 14.4.            The Versatile and Patient Friendly Nature of these Diagnostic Tools Cater to a Wide Range        of Applications 14.5.            The Interest is Gradually Rising with Participation of Several Start-ups Across Different        Geographies 14.6.            In Addition to Liquid Biopsy, Development of Other Non-Invasive Tests will Further        Strengthen the Ongoing Innovation 14.7.            Rising Venture Capital Support is Indicative of a Lucrative Future Potential 14.8.            Primarily Led by Liquid Biopsy, the Non-Invasive Cancer Diagnostics Market has Emerged        as a Multi-Billion Dollar Market 15.1.            Chapter Overview 15.2.            Interview Transcript: Shibichakravarthy Kannan, Founder & Chief Executive Officer,        Theranosis Life Sciences 15.3.            Interview Transcript: Anton Iliuk, President and Chief Technology Officer, Tymora Analytical        Operations 15.4.            Interview Transcript: Peter French, Strategic Technology Advisor, Sienna Cancer        Diagnostics 15.5.            Interview Transcript: Joachim Fluhrer, Founder and Medical Director, Genostics 15.6.            Interview Transcript: Brad Walsh, Chief Executive Officer, Minomic International 15.7.            Interview Transcript: Catalina Vasquez, Chief Operating Officer, Nanostics 15.8.            Interview Transcript: Burkhard Jansen, Chief Medical Officer, DermTech 15.9.            Interview Transcript: Frank Szczepanski, President and CEO, IVDiagnostics 15.10.          Interview Transcript: Riccardo Razzini, Sales and Marketing Manager, LCM Genect 15.11.          Interview Transcript: Nathalie Bernard, Marketing Director, OncoDNA 15.12.          Interview Transcript: Abizar Lakdawalla, Founder, Proxeom 15.13.          Interview Transcript: Mark Li, CEO, Resolution Bioscience 15.14.          Interview Transcript: Christer Ericsson, Chief Scientific Officer, iCellate Medical 15.15.          Interview Transcript: Philippe Nore, CEO and Co-founder, MiNDERA 15.16.          Interview Transcript: Jake Micallef, Chief Scientific Officer, VolitionRx Contact Details Gaurav Chaudhary +1 (415) 800 3415 [email protected] Source: Free Articles from ArticlesFactory.com .